Leishmaniasis - Pipeline Insight, 2024

Leishmaniasis - Pipeline Insight, 2024

DelveInsight’s, “Leishmaniasis - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Leishmaniasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Leishmaniasis Understanding

Leishmaniasis: Overview

Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

""Leishmaniasis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leishmaniasis pipeline landscape is provided which includes the disease overview and Leishmaniasis treatment guidelines. The assessment part of the report embraces, in depth Leishmaniasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leishmaniasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Leishmaniasis R&D. The therapies under development are focused on novel approaches to treat/improve Leishmaniasis.

Leishmaniasis Emerging Drugs Chapters

This segment of the Leishmaniasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leishmaniasis Emerging Drugs

• LXE408: Novartis

DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome – as a potential new oral treatment for visceral leishmaniasis. Currently, it is in Phase II stage of development.

• GSK 3494245: GlaxoSmithKline

GSK 3494245 is a Proteasome inhibitor being developed by GlaxoSmithKline for the treatment of patients with Leishmaniasis. The drug is currently in phase 1 stage of development.

Further product details are provided in the report……..

Leishmaniasis: Therapeutic Assessment

This segment of the report provides insights about the different Leishmaniasis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Leishmaniasis

There are approx. 4+ key companies which are developing the therapies for Leishmaniasis. The companies which have their Leishmaniasis drug candidates in the most advanced stage, i.e. phase II include, Novartis.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Leishmaniasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leishmaniasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leishmaniasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leishmaniasis drugs.

Leishmaniasis Report Insights

• Leishmaniasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leishmaniasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Leishmaniasis drugs?
• How many Leishmaniasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leishmaniasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leishmaniasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leishmaniasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• GlaxoSmithKline
• MedC Biopharma Corporation
• Drugs for Neglected Diseases Initiative Foundation
• Infan Industria Quimica Farmaceutica Nacional

Key Products

• LXE408
• GSK 3494245
• GSK 3186899
• DNDI 6148
• DMD 2010
• DNDI 6174
• 18-Methoxycoronaridine